Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 ...

The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...

The FDA has issued a complete response letter to AstraZeneca regarding its application for subcutaneous administration of ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in ...

February 2026 Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus The US Food and Drug Administration (FDA) issued a complete response letter (CRL) ...

The US Food and Drug Administration rejected a subcutaneous version of AstraZeneca Plc’s lupus medicine that would make it easier to administer.

Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered ...

Many professionals report awareness, but few actively prescribe the self-administered injectable contraceptive DMPA.

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

Please provide your email address to receive an email when new articles are posted on . Subcutaneous delivery reduced administration time from several hours to less than 5 minutes. Although unexpected ...

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...